Restoration of wild-type conformation to full-length and truncated p53 proteins: Specific effects of ATP and ADP

Cancer Biology and Therapy

Volumn 3, Issue 7, 2004, Pages 634-637

  Warnock, Lorna J ^a   Raines, Sally A ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

ADP; ATP; Mutant; p53 protein; Wild type

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; EPITOPE; MONOMER; PROLINE; PROTEIN P53; RECOMBINANT PROTEIN;

ANALYTIC METHOD; ARTICLE; BACULOVIRUS; BINDING SITE; CONJUGATION; IN VITRO STUDY; REGULATORY MECHANISM; RENATURATION; WILD TYPE; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PROTEIN BINDING; PROTEIN CONFORMATION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; BACULOVIRIDAE; BINDING SITES; EPITOPES; MICE; PROLINE; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 16644376554     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.7.915     Document Type: Article

References (31)

1. Ljungman M. Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress. Nature Neoplasia 2000; 2:208-25.
2. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93.
3. Oren M, Rotter V. Introduction: p53 - the first twenty years. Cell Mol Life Sci 1999; 55:9-11.
4. Prives C, Hall PA. The p53 pathway. J Path 1999; 187:112-6.
5. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15:164-71.
6. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene 2000; 19:1245-56.
7. Chene P. The role of tetramerization in p53 function. Oncogene 2001; 20:2611-7.
8. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994; 265:346-55.
9. Ayed A, Mulder FAA, Yi G-S, Lu Y, Kay LE, Arrowsmith CH. Latent and active p53 are identical in conformation. Nature Structural Biology 2001; 8:756-60.
10. Hupp TR, Lane DP, Ball KL. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000; 352:1-17.
11. Okorokov AL, Warnock L, Milner J. Effect of wild-type, S15D and R175H p53 proteins on DNA end joining in vitro: Potential mechanism of DNA double-strand break repair modulation. Carcinogenesis 2002; 23:549-57.
12. Hainaut P, Milner J. A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53. Cancer Research 1993; 53:1739-42.
13. Wang PL, Sait F, Winter G. The 'wildtype' conformation of p53: Epitope mapping using hybrid proteins. Oncogene 2001; 20:2318-24.
14. Hainaut P, Milner J. Interaction of heat-shock protein 70 with p53 translated in vitro: Evidence for a role in thregulation of p53 conformation. EMBO J 1992; 10:3513-20.
15. Okorokov AL, Milner J. An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes. Mol Cell Biol 1999; 19:7501-10.
16. Milner J. Flexibility: The key to p53 function? TIBS 1995; 20:49-51.
17. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286:2507-11.
18. Bykov VJN, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Medicine 2002; 8:282-9.
19. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The mutant p53-conformation modification drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 2002; 1:47-55.
20. Cook A, Milner J. Evidence for allosteric variants of wild-type p53, a tumour suppressor protein. Br J Cancer 1990; 61:548-52.
21. Milner J, Cook A, Sheldon M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene 1987; 1:453-455.
22. McLure KG, Lee PW. A PAb240+ conformation of wild-type p53 binds to DNA. EMBO J 1999; 18:763-70.
23. ARF contribution to the regulation of mutant p53 stability. J Mol Biol 1999; 295:1009-21.
24. Sugikawa E, Tsunoda S, Nakanishi N, Ohashi M. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. Anticancer Research 2001; 21:2671-2676.
25. Ruaro E, Collavin L, Del Sal G, Haffner R, Oren M, Levine AJ, et al. A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas 1. Proc Nat Acad Sci USA 1997; 94:4675-80.
26. Jiang M, Axe T, Holgate R, Rubbi CP, Okorokov AL, Mee T, et al. p53 binds the nuclear matrix in normal cells: Binding involves the proline-rich domain of p53 and increases following genotoxic stress. Oncogene 2001; 20:5449-58.
27. Liu G, Xia T, Chen X. The activation domains, the proline-rich region, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J Biol Chem 2003; 278:17557-65.
28. Friedlander P, Legros Y, Soussi T, Prives C. Regulation of mutant p53 temperaturesensitive DNA binding. J Biol Chem 1996; 271:25468-78.
29. Hansen S, Hupp TR, Lane DP. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J Biol Chem 1996; 271:3917-24.
30. Jayaraman L, Freulich E, Prives C. Functional dissection of p53 tumor suppressor protein. Methods Enzymol 1997; 283:245-56.
31. Mee T, Okorokov AL, Metcalfe S, Milner J. Proteolytic cleavage of p53 mutants in response to mismatched DNA. Br J Cancer 1999; 81:212-8.